NCI CTEP-Approved Trials for the Month of October

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase I

9588: A Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Memorial Sloan Kettering Cancer Center; Sauter, Craig S. (212) 639-3460

9849: A Phase I Study of a Continuous Intravenous Infusion of Recomninant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers. NCI Lymphoid Malignancies Branch; Conlon, Kevin C. (301) 402-2913

9850: A Phase I Study of Intravenous Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer. NCI Lymphoid Malignancies Branch; Waldmann, Thomas Alexander. (301) 496-6656

9851: Haploidentical Donor Natural Killer (NK) Cell Infusion with Intravenous Recombinant Human IL-15 (rhIL-15) in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML). University of Minnesota Medical Center-Fairview; Miller, Jeffrey Steven. (612) 624-0123


Phase II

CITN-09: A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC). Cancer Immunotherapy Trials Network; Nghiem, Paul. (206) 221-2632

CITN-10: A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides / Sézary Syndrome. Cancer Immunotherapy Trials Network; Kohrt, Holbrook E. K. (650) 723-8222 x 22047


Phase II/III

A071102: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation. Alliance for Clinical Trials in Oncology; Sarkaria, Jann N. (507) 284-8227


Phase III

A221303: Randomized Study of Early Palliative Care Integrated with Standard Oncology Care Versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies. Alliance for Clinical Trials in Oncology; Temel, Jennifer Gold. (617) 726-2514

AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy). Children’s Oncology Group; Teachey, David Trent. (267) 426-5802


Pilot Phase

9603: Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma. Ohio State University Medical Center; Hofmeister, Craig C. (614) 293-3507


Other Phases

A151205: Analysis of the Association Between HSP110deltaE9 and Prognosis in Patients with Stage III Colon Cancers with Microsatellite Instability. Alliance for Clinical Trials in Oncology; Goldberg, Richard Miles. (614) 366-6355

ARST14B1-Q: Validation of NRAS, KRAS, HRAS, PIK3CA, BCOR, TP53, NF1, FGFR4, FBXW7, CTNNB1 Mutations in Pediatric Rhabdomyosarcoma. Children’s Oncology Group; Khan, Javed. (301) 439-2937

E1697T1: Quantification of RNA Transcripts of Immune Response Genes in Primary Melanoma Tumors Using NanoString Technology to Establish Prognostic Immune Gene Signature in Patients with Stage II-III Resected Primary Melanoma Tumors. ECOG-ACRIN Cancer Research Group; Saenger, Yvonne. (646) 425-5734

E2404T2: Effect of Somatic RhoA Mutation in Peripheral T Cell Lymphoma (PTCL) on Treatment Outcomes. ECOG-ACRIN Cancer Research Group; Jagadeesh, Deepa. (216) 444-0857

E2993T5: Leukemia Xenografting for Samples From Patients with B-Cell Acute Lymphoblastic Leukemia Enrolled in E2993 Clinical Trial. ECOG-ACRIN Cancer Research Group; Muschen, Markus. (415)502-0388

NRG-CR-TS001: Validation of Predictive Models for the Degree of Benefit From the Addition of Oxaliplatin to Adjuvant FULV in the Treatment of Stage II and III Colon Cancer. NRG Oncology; Pogue-Geile, Katherine. (412) 359-8774

YOU MAY BE INTERESTED IN

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Login